GLP-1 Muscle Loss: Protein and Strength Signals

What the clinical trials actually found

Secondary reporting on the STEP 1 trial, the pivotal trial behind semaglutide (marketed as Wegovy), along with a related SUSTAIN 8 body-composition analysis, describes roughly 39-40% of total weight lost as lean mass. That figure comes from semaglutide-specific research and shouldn't be treated as a number that applies to every GLP-1 medication.

A separate DXA-based sub-study of STEP 1, involving 140 participants, adds an important nuance. It found total lean body mass fell by about 9.7% from baseline in the semaglutide group, but fat mass fell even faster, with total fat mass down about 19.3% and visceral fat down about 27.4%. Because fat dropped by more than lean tissue, the proportion of lean mass relative to total body mass actually increased by roughly 3 percentage points over the study. Participants ended up with a body composition that was, proportionally, more muscle and less fat, even though the absolute amount of lean tissue had gone down. That's one trial's finding, not a universal guarantee, but a useful counterweight to reading lean-mass numbers as pure alarm.

SURMOUNT-1, the pivotal trial behind tirzepatide (marketed as Zepbound), reported a different pattern: fat mass fell by roughly 33-36% while lean mass fell by about 10-11%, depending on age group, which works out to roughly one-quarter of total weight lost being lean mass. That's a notably different ratio than the semaglutide figures above, and it's worth being precise about which drug a given statistic describes. The STEP 1 findings apply to semaglutide, the SURMOUNT-1 findings apply to tirzepatide, and the two shouldn't be treated as interchangeable or averaged together.

Across the wider research literature on GLP-1s and other forms of rapid weight loss, lean mass is commonly reported to account for somewhere between 20% and 50% of total weight lost, a range broadly similar to calorie-restriction diets and bariatric surgery. Some lean-mass loss appears to be a fairly ordinary part of significant weight loss by almost any method, not something unique to GLP-1 drugs, which is why researchers describe this as documented and worth monitoring, rather than settled fact in either direction.

Protein intake commonly discussed for preserving lean mass

General population protein guidance, often cited around 0.8 grams per kilogram of body weight per day, is described by multiple dietitian and clinical sources as likely insufficient during intentional, rapid weight loss, including GLP-1-driven weight loss, because inadequate protein during a significant caloric deficit raises the chance that more of the weight lost is lean muscle rather than fat.

A commonly cited general range for people intentionally losing weight, including on GLP-1 therapy, is 1.2 to 1.6 grams of protein per kilogram of body weight per day, roughly 0.55 to 0.73 grams per pound. Some sources reference a related figure of about 1.5 grams per kilogram of lean body mass per day, and others use a more conservative band based on ideal rather than actual body weight. Alongside a daily total, dietitian commentary commonly frames intake as roughly 25 to 40 grams of protein per meal, across three to four eating occasions a day, since the muscle-building response to a single meal is thought to level off above that range.

No single authoritative, universally agreed protein number exists specifically for GLP-1 users; the 1.2 to 1.6 gram per kilogram range above is simply the figure most consistently repeated across the dietitian- and clinician-authored sources behind this page. These are general population reference ranges, not a personalized prescription, and actual needs vary with body size, age, activity level, kidney function, and other health conditions, which is why getting a personal protein target from a doctor or registered dietitian is the approach most consistently recommended in that research.

Resistance training as a commonly recommended complement

Alongside protein intake, resistance and strength training is the other lever that clinical and dietitian commentary consistently points to for helping preserve lean mass during GLP-1-assisted weight loss. Protein alone is generally described as necessary but not sufficient, since muscle tissue tends to respond to a mechanical stimulus, which is where resistance exercise comes in, and pairing the two is the combination most often discussed in the research behind this page.

General exercise guidance commonly frames resistance training around two to three sessions a week, though that's general population guidance rather than a formal, GLP-1-specific prescription; no major medical body appears to have published an exact GLP-1-specific training-frequency recommendation. Some research on real-world GLP-1 use also links reduced exercise tolerance with steeper lean-mass decline, part of why overall activity, not just formal strength training, tends to come up alongside protein here. Starting a new exercise routine, especially for people new to exercise, older adults, or those with joint or cardiovascular conditions, is an area where checking with a clinician or physical therapist first is commonly advised. Pokii's Apple Health integration centers on nutrition, water, weight, and body measurements for the GLP-1 journey. What Pokii supports for muscle retention is covered below.

Emerging investigational research worth watching

A newer area of research is testing whether pairing a GLP-1 medication with a separate, muscle-targeted drug can reduce lean-mass loss. The BELIEVE trial, a phase 2 study combining bimagrumab with semaglutide, reported 2026 data showing that at week 72, the high-dose combination produced 22.1% body weight loss, versus 15.7% for semaglutide alone and 10.8% for bimagrumab alone. Notably, 92% of the weight lost in the combination group came from fat mass, versus 76% for semaglutide alone, meaning the combination reduced the share of total weight loss coming from lean mass. Bimagrumab is investigational and not an FDA-approved product.

A separate phase 2 trial, EMBRAZE, tested apitegromab, a different investigational muscle-preserving drug, added to tirzepatide or semaglutide; reporting on it describes apitegromab preserving roughly 55% more lean mass than tirzepatide alone. Apitegromab, too, is investigational and not an approved treatment.

Both are still active clinical trials, not approved treatment options, and muscle-preserving combination drugs for GLP-1 users remain an unsettled, still-developing area as of this writing — an emerging area to watch rather than something currently available.

Watching the trend with Pokii's nutrition dashboard and weight trend

Pokii's nutrition dashboard tracks calories, protein, carbohydrates, fat, fiber, sugar, and sodium, sourced from Apple Health, including entries from Pokii's own AI meal-scan feature. That gives a way to monitor protein intake day to day against a general range like the 1.2 to 1.6 grams per kilogram figure discussed above. Pokii Pokii also includes custom nutrition targets, so a personal protein target set with a clinician's or dietitian's input can be tracked directly against actual intake.

On the body-composition side, Pokii's weight trend line, available in Pokii, smooths day-to-day fluctuation into a clearer overall trajectory, alongside a target weight and projected goal date. Pokii can also read lean body mass from Apple Health and plot it as a chart overlay next to weight, in Pokii, though that depends on another Health-connected source, such as a compatible smart scale, supplying lean body mass data; Pokii itself doesn't measure lean mass directly.

Put together, the nutrition dashboard and the weight and lean-mass trend give a way to keep an eye on protein intake and overall body-composition trajectory over the course of GLP-1 treatment. Pokii is a tracking and education tool, and it does not diagnose, treat, or replace a conversation with a prescriber or dietitian about an individual muscle-preservation plan.